Michael Jorrin, "Doc Gumshoe"

Author Bio

Michael Jorrin,
I have been a medical writer for about 25 years; before that I was a documentary film maker, and some of my films were about medical subjects. I am not a physician, but I have a pretty good scientific background. I wouldn’t dream of recommending any kind of treatment to anyone, and I cannot give medical advice. However, I understand the medical literature and the data and evidence behind it, and I have an inquiring and skeptical turn of mind. I scrutinize and question and, sometimes, challenge the positions of some of the established health-care organizations as well as the marketers of health information. Eternal vigilance is a small price to pay for health. — Michael Jorrin (aka DocGumshoe) Michael Jorrin is a paid contributor to Stock Gumshoe, he has agreed to our trading restrictions but he chooses his own topics and his words and opinions are his own.

Author Archives

What’s New this Summer?

[ed. note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, is a longtime medical writer (not a doctor) who writes for us a couple times a month about health issues and trends.  He does not typically write about specific investment opportunities, but has agreed to our trading restrictions… as with all of our authors, […]

Bulletins from the Cardiac Front

[Ed note: Here is our latest piece from “Doc Gumshoe”, who is a medical writer (not a doctor) who shares his wisdom with us at Stock Gumshoe a couple times a month.  He does not typically write specifically about investments, but does write about publicly traded companies and their drugs, and has agreed to our trading […]

Antibiotic Resistance: What’s Happening?

[ed. note: Michael Jorrin, who I call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes for us about medicine and health a couple times a month. He has agreed to our trading and disclosure restrictions, but does not generally write directly about investment ideas. His ideas, thoughts and words are his […]

The Miracle Cures Keep Coming 

[ed. note: Michael Jorrin, who I call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes for us about medicine and health a couple times a month. He has agreed to our trading and disclosure restrictions, but does not generally write directly about investment ideas. His ideas, thoughts and words are his […]

End of Winter Miscellany

[ed. note: Michael Jorrin, who I like to call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes about non-financial health and medical issues for us a couple times a month (past submissions can be found on his author page here). Like all of our authors, he chooses his own topics and […]

Responses to Recent Comments

[ed note: Michael Jorrin is longtime medical writer who has been sharing his thoughts with our readers as “Doc Gumshoe” for several years (he’s not a doctor, I gave him the name). He generally covers medical and health news and sometimes health promotions and hype, but he rarely opines about investments or specific stocks. All […]

Thanksgiving Leftovers and Short Takes

[ed note: Michael Jorrin is longtime medical writer who has been sharing his thoughts with our readers as “Doc Gumshoe” for several years (he’s not a doctor, I gave him the name). He generally covers medical and health news and sometimes health promotions and hype, but he rarely opines about investments or specific stocks. All […]

Supplements and Drugs: the Feud Redux

[ed note: Michael Jorrin is longtime medical writer who has been sharing his thoughts with our readers as “Doc Gumshoe” for several years (he’s not a doctor, I gave him the name). He generally covers medical and health news and sometimes health promotions and hype, but he rarely opines about investments or specific stocks. All […]

Recent Author Comments

On What’s Happening on the Alzheimer’s/Dementia Front?
Thanks again for all the comments! To those who urged me to look at BIIB 037, now called aducanumab, I discussed it in some detail in a piece that posted nearly two years ago, in December 2015 - "Alzheimer's: Current Options and Possible Treatment Appro[...]
On The Miracle Cures Keep Coming 
Dear Angela< Of course you can't patent nature. But many - perhaps the majority - of pharmaceuticals are based on naturally-occurring substances. The drug companies identify the substance, whether it's a molecule or a complex biologic enti[...]
On Pain Management Versus Opioid Abuse: Glimmers of Light
The fentanyl drug I was referring to is carfentanyl, which is used as an anaesthetic for large animals. It is fatal to humans even in tiny doses. Beware![...]
On Pain Management Versus Opioid Abuse: Glimmers of Light
The many deeply heartfelt comments bear out the dilemma. The real drug addicts are making life miserable for the immense numbers of people who are living with severe pain, and the desire of the medical and pharmaceutical sectors to protect themselves fro[...]
On Pain Management Versus Opioid Abuse: Glimmers of Light
Once again, many thanks for all the comments. My position in general is that chronic pain is at least as worthy of serious attention as the opioid addiction crisis. Individuals as well as the community and society are severely impacted by both. To th[...]
On Pain Management Versus Opioid Abuse: Glimmers of Light
The cause of joint pain is usually inflammation and prednisone acts to squelch that, but long term use poses risks. Good luck![...]
On Pain Management Versus Opioid Abuse: Glimmers of Light
Oxycodone is not exactly "prohibitive" - retail cost is about $60 for 120 5 mg tablets, and coupons to lower the price to about $20 for 120 tablets are commonly available. It's cheap, and that's why some insurers prefer it to lower-risk alternatives. B[...]
On Pain Management Versus Opioid Abuse: Glimmers of Light
Vic, I'll be on the lookout for more news about NKTR-181, Thanks & best, MJ[...]
On What's "The Lazarus Project" and the "Greatest Medical Innovation of Our Time?"
Naloxone is here to stay. Delivery mechanisms will change over time. Can't comment on Opiant in the short run, but dubious in the long run.[...]
On Pain Management Versus Opioid Addiction: A Troubling Quandary
Not sure I get your point. Opioid overdoses will essentially paralyze the respiratory system and lead to death. Fentanyl will do the same thing, but in quite small quantities. Engogenous morphine is not a threat, and exogenous morphine, in carefully [...]
On Pain Management Versus Opioid Addiction: A Troubling Quandary
Correct! Nektar's drug, so far named only NKTR-181, is not yet approved, but is FDA fast-tracked. I'm working on my next blog right now, should finish in a couple of days, & will have quite a lot more to say about that promising drug, as well as ot[...]
On Lichtenfeld's "Genesis Cure" -- "This single technology could wipe 4,800 incurable diseases off the face of the Earth"
Some form of CRISPR technology will successfully target A disease - not hundreds or thousands. And some CRISPR outfit will make a mint. But I ain't young enough to wait. Good luck to those who are![...]
On "Sig-1" and the Reversal of "79-Year-Old Grandma's Alzheimer's" pitched by Casey
I have looked at it & will do some more checking, but not right away - just about to leave on vacation to a tiny island off the coast of Maine - back in September. Thanks & best![...]
On What’s New this Summer?
Thanks for the many interesting & provocative comments. I will be on vacation on a tiny isolated island off the coast of Maine for a couple of weeks with no email access, but I will respond when we get back in September. Best to all, Michael Jorri[...]
On What’s New this Summer?
From what I have read, Genentech is only now launching a Phase 1 study in their DLK inhibitor, GDC-0134. I have the utmost respect for Genentech & my fingers are crossed as well - not only for my fellow humans, but for myself as well. Who knows wha[...]
On What’s New this Summer?
Thanks for the comment, Nick. The Phase 3 results have not been published yet, but Northwest Bio has been putting out partial results on some patients who were not included in the Phase 3 study. These appear to be promising, but so far it's anecdotal. [...]
On Hodge's "November 1: New FDA Mandate Sends This Device Into EVERY Restaurant in America"
Unless this outfit has a miraculous new method of distinguishing pathogens from the myriad harmless organisms that abound in our food and indeed in the environment, it's going nowhere. Each infectious organism has its own specific sneaky method of doing[...]
On Responses to Comments and a Proposed Study of Alcoholic Beverages
A dry cough is a common lisinopril side effect. Physicians tend to stay away from it in patients who have respiratory ailments like asthma. Fortunately there are lots of antihypertensives that work just fine.[...]
On Responses to Comments and a Proposed Study of Alcoholic Beverages
Quick answer - I agree with the philosopher Benedict Spinoza who though that there was life in everything in the universe - not just animals and plants. What is life if not divinity?[...]
On Responses to Comments and a Proposed Study of Alcoholic Beverages
Many, many thanks to Dr KSS for his comments about the hepatic effects of alcohol in women!!![...]

This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.